Date
21 January 2017
The Receptos acquisition provides a "transformational opportunity" for Celgene, says the latter's CEO Bob Hugin. Photo: Bloomberg
The Receptos acquisition provides a "transformational opportunity" for Celgene, says the latter's CEO Bob Hugin. Photo: Bloomberg

Celgene to acquire Receptos for US$7.2 bln

Celgene Corp., a US cancer drug maker, has agreed to acquire California-based Receptos Inc. in a deal worth US$7.2 billion.

Celgene will pay US$232 a share in cash for the acquisition which is expected to close in the current quarter, Bloomberg News reported.

The deal will give Celgene a drug, ozanimod, that is in late stage development for treatment of inflammatory bowel disease and multiple sclerosis.

Receptos, based in San Diego, went public in May 2013, at US$14 a share.

So the acquisition represents a more than 16-fold return in just over two years, the report noted.

“The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas,” Reuters quoted Celgene CEO Bob Hugin as saying on a conference call Tuesday.

– Contact us at [email protected]

CG/RC

EJI Weekly Newsletter